JAMA Medical News Clinical Highlights From ASCO 2025
15 snips
Jun 27, 2025 Kimmie Ng, MD, MPH, is an associate editor at JAMA and leads the Division of Gastrointestinal Oncology at Dana-Farber. She shares groundbreaking insights from ASCO's annual meeting, including how intensive exercise can boost survival rates in advanced colon cancer patients. Ng highlights the significant link between diet, exercise, and cancer outcomes, as well as findings on GLP-1 receptor agonists reducing colorectal cancer risk. Additionally, she discusses innovations in cancer screening and critiques traditional clinical trial metrics, advocating for patient-centered outcomes.
AI Snips
Chapters
Transcript
Episode notes
Exercise Boosts Colon Cancer Survival
- The CHALLENGE trial showed structured exercise improves disease-free survival in stage 3 colon cancer.
- The survival benefit is comparable to many FDA-approved drugs for colon cancer.
Diet and Exercise Affect Survival
- A pro-inflammatory diet correlates with worse survival in stage 3 colon cancer.
- High exercise and low inflammatory diet together yield the best overall survival.
GLP-1 Drugs and Cancer Risk
- GLP-1 receptor agonists users showed modestly lower risk of obesity-related cancers, especially colorectal cancer.
- It's unclear if this is due to weight loss or direct drug effects.